Picture of Myriad Genetics logo

MYGN — Myriad Genetics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

Myriad Genetics Inc reports results for the quarter ended in September 30 - Earnings Summary

* Myriad Genetics Inc  MYGN.OQ  reported quarterly adjusted
earnings of 6 cents​​ per share for the quarter ended September
30, higher than the same quarter last year, when the company
reported EPS of -3 cents.  The mean expectation of
fifteen analysts for the quarter was for earnings of 2 cents per
share. Wall Street expected results to range from zero cents
to 5 cents per share.
    * Revenue rose 11.2% to $213.30 million from a year ago;
analysts
expected $210.73 million. 
    * Myriad Genetics Inc's reported EPS for the quarter was a
loss
of 24 cents​.
    * The company reported a quarterly loss of $22.1 million.
    * Myriad Genetics Inc shares had fallen by 35.9% this
quarter and
lost 8.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 23.4%
in the last three months.​ 
    * In the last 30 days, two analysts negatively revised
earnings
estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 4
"hold" and 4 "sell" or "strong sell." 
    * The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "hold"

Wall Street's median 12-month price target for Myriad Genetics
Inc is 30.00 
This summary was machine generated from LSEG data November 8 at
04:41 a.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      0.02           0.06           Beat
 Jun. 30 2024      -0.01          0.05           Beat
 Mar. 31 2024      -0.10          -0.01          Beat
 Dec. 31 2023      0.01           0.04           Beat

Recent news on Myriad Genetics

See all news